Targeting the ACOD1-itaconate axis stabilizes atherosclerotic plaques
暂无分享,去创建一个
A. Michelucci | Bauke V. Schomakers | M. van Weeghel | M. D. de Winther | A. Neele | M. Toom | Kyra E. de Goede | S. Verberk | J. van den Bossche | G. Griffith | M. Reiche | D. Heister | Lisa Willemsen | Linda Beckers | Xanthe A M H van Dierendonck | Aurélie Poli | Marion J Gijbels | Karl J. Harber | Cindy P.A.A. van Roomen | Frida L-H Mogensen | Helga E. de Vries
[1] Yuqing Zhu,et al. Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors , 2023, Nature communications.
[2] T. van der Poll,et al. Inflammatory and glycolytic programs underpin a primed blood neutrophil state in patients with pneumonia , 2023, iScience.
[3] K. Ley,et al. Deleting interleukin-10 from myeloid cells exacerbates atherosclerosis in Apoe−/− mice , 2022, Cellular and Molecular Life Sciences.
[4] Kai Song,et al. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat , 2022, Frontiers in Cardiovascular Medicine.
[5] G. Pasterkamp,et al. Sterol-regulated transmembrane protein TMEM86a couples LXR signaling to regulation of lysoplasmalogens in macrophages , 2022, Journal of lipid research.
[6] W. Wiersinga,et al. The Platelet Lipidome Is Altered in Patients with COVID-19 and Correlates with Platelet Reactivity , 2022, Thrombosis and haemostasis.
[7] Gang Pan,et al. Occurrences and Functions of Ly6Chi and Ly6Clo Macrophages in Health and Disease , 2022, Frontiers in Immunology.
[8] R. Houtkooper,et al. Polar metabolomics in human muscle biopsies using a liquid-liquid extraction and full-scan LC-MS , 2022, STAR protocols.
[9] Yu-zhou Gui,et al. Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms , 2022, Frontiers in Cardiovascular Medicine.
[10] Rabina Mainali,et al. Itaconate and Its Derivatives Repress Early Myogenesis In Vitro and In Vivo , 2022, Frontiers in Immunology.
[11] M. Crabtree,et al. Itaconate as an inflammatory mediator and therapeutic target in cardiovascular medicine , 2021, Biochemical Society transactions.
[12] G. Schabbauer,et al. Lipid Scavenging Macrophages and Inflammation. , 2021, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[13] Huiru Tang,et al. Itaconic acid exerts anti-inflammatory and antibacterial effects via promoting pentose phosphate pathway to produce ROS , 2021, Scientific Reports.
[14] Lina Yu,et al. The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities , 2021, Frontiers in Chemistry.
[15] Arwen W. Gao,et al. Metabolomics and lipidomics in Caenorhabditis elegans using a single-sample preparation , 2021, Disease models & mechanisms.
[16] D. M. Simons,et al. Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages , 2020, Nature metabolism.
[17] A. Nègre-Salvayre,et al. Role of reactive oxygen species in atherosclerosis: Lessons from murine genetic models. , 2020, Free radical biology & medicine.
[18] E. Pearce,et al. Triacylglycerol synthesis enhances macrophage inflammatory function , 2020, Nature Communications.
[19] L. O’Neill,et al. Krebs Cycle Reborn in Macrophage Immunometabolism. , 2020, Annual review of immunology.
[20] Tessa J. Barrett. Macrophages in Atherosclerosis Regression , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[21] M. Garcia-Gil,et al. Purine-Metabolising Enzymes and Apoptosis in Cancer , 2019, Cancers.
[22] Ira Tabas,et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities , 2019, Nature Reviews Cardiology.
[23] M. Monami,et al. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials , 2019, Journal of Endocrinological Investigation.
[24] P. Ridker. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis , 2019, Circulation research.
[25] Maxim N. Artyomov,et al. Itaconate: the poster child of metabolic reprogramming in macrophage function , 2019, Nature Reviews Immunology.
[26] R. Spang,et al. Correcting for natural isotope abundance and tracer impurity in MS-, MS/MS- and high-resolution-multiple-tracer-data from stable isotope labeling experiments with IsoCorrectoR , 2018, Scientific Reports.
[27] S. Ferdinandusse,et al. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[28] Charlotte L. Scott,et al. Macrophages and lipid metabolism , 2018, Cellular immunology.
[29] S. Denis,et al. Pyruvate dehydrogenase complex plays a central role in brown adipocyte energy expenditure and fuel utilization during short-term beta-adrenergic activation , 2018, Scientific Reports.
[30] K. Moore,et al. Regulation of macrophage immunometabolism in atherosclerosis , 2018, Nature Immunology.
[31] John Szpyt,et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 , 2018, Nature.
[32] N. Perrimon,et al. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. , 2017, Cancer cell.
[33] L. Joosten,et al. Monocyte and macrophage immunometabolism in atherosclerosis , 2017, Seminars in Immunopathology.
[34] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[35] L. O’Neill,et al. Macrophage Immunometabolism: Where Are We (Going)? , 2017, Trends in immunology.
[36] P. Ridker. How Common Is Residual Inflammatory Risk? , 2017, Circulation research.
[37] Hao Wu,et al. Eating the Dead to Keep Atherosclerosis at Bay , 2017, Front. Cardiovasc. Med..
[38] R. Xavier,et al. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages , 2016, Cell.
[39] Angela C. M. Luyf,et al. Lipidomic analysis of fibroblasts from Zellweger spectrum disorder patients identifies disease-specific phospholipid ratios[S] , 2016, Journal of Lipid Research.
[40] Maxim N. Artyomov,et al. Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation. , 2016, Cell metabolism.
[41] J. Rathmell,et al. A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.
[42] Christian M. Metallo,et al. Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels* , 2016, The Journal of Biological Chemistry.
[43] K. Bornfeldt,et al. Macrophage Phenotype and Function in Different Stages of Atherosclerosis. , 2016, Circulation research.
[44] K. Moore,et al. Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.
[45] Kathryn E. Crosier,et al. Immunoresponsive gene 1 augments bactericidal activity of macrophage-lineage cells by regulating β-oxidation-dependent mitochondrial ROS production. , 2013, Cell metabolism.
[46] R. Balling,et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production , 2013, Proceedings of the National Academy of Sciences.
[47] G. Radda,et al. The Cycling of Acetyl-Coenzyme A Through Acetylcarnitine Buffers Cardiac Substrate Supply: A Hyperpolarized 13C Magnetic Resonance Study , 2012, Circulation. Cardiovascular imaging.
[48] K. Ley,et al. NR4A1 (Nur77) Deletion Polarizes Macrophages Toward an Inflammatory Phenotype and Increases Atherosclerosis , 2012, Circulation research.
[49] V. de Waard,et al. Bone Marrow–Specific Deficiency of Nuclear Receptor Nur77 Enhances Atherosclerosis , 2012, Circulation research.
[50] S. Xanthoulea,et al. Myeloid IκBα Deficiency Promotes Atherogenesis by Enhancing Leukocyte Recruitment to the Plaques , 2011, PloS one.
[51] P. Tontonoz,et al. LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor , 2009, Science.
[52] D. Rader,et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. , 2007, The Journal of clinical investigation.
[53] F. Stephens,et al. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle , 2007, The Journal of physiology.
[54] G. Hansson. Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.
[55] S. Akira,et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] K. Moore,et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.
[57] D. Schwartz,et al. Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.
[58] D. Mangelsdorf,et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Bureau,et al. Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.
[60] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[61] R. Evans,et al. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.
[62] R. Evans,et al. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.
[63] B. Staels,et al. Macrophage subsets in atherosclerosis , 2015, Nature Reviews Cardiology.